Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

BACKGROUND: Aromatase inhibitors (AI) reduce recurrence and death in patients with early-stage hormone receptor-positive (HR +) breast cancer. Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common and may lead to early AI discontinuation. The objective of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hertz, Daniel L., Smith, Karen Lisa, Zong, Yuhua, Gersch, Christina L., Pesch, Andrea M., Lehman, Jennifer, Blackford, Amanda L., Henry, N. Lynn, Kidwell, Kelley M., Rae, James M., Stearns, Vered
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239354/
https://www.ncbi.nlm.nih.gov/pubmed/34211496
http://dx.doi.org/10.3389/fgene.2021.662734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8239354/
https://www.ncbi.nlm.nih.gov/pubmed/34211496
http://dx.doi.org/10.3389/fgene.2021.662734

Ejemplares similares